title: [miR-29b Reduces Cisplatin Resistance of Gastric Cancer Cell by Targeting PI3K/Akt Pathway].
abstract: OBJECTIVE
  To investigate the regulatory effect of miR-29b on gastric cells' resistance to cisplatin.
  
  
  METHODS
  The expression of miR-29b in gastric cancer cell line treated with cisplatin concentration gradient was detected using quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blotting. CCK8 was used to measure the cell viability after cisplatin treatment in condition of miR-29b knock-down and overexpression.
  
  
  RESULTS
  The expression of miR-29b was significantly upregualted by cisplatin treatment,while its target gene AKT2 was downregulated. The up-regulation of miR-29b enhanced the sensitivity of gastric cancer cells to cisplatin,while the knock-down of miR-29b enhanced the cisplatin resistance. Rescue experiments demonstrated that the miR-29b might regulate cisplatin resistance of gastric cancer cell by targeting PI3K/Akt pathway. The expressions of the other two members of miR-29 family, miR-29a/c, were promoted by cisplatin treatment,but they had no significant effect on gastric cancer cell's resistance to cisplatin.
  
  
  CONCLUSIONS
  miR-29b can enhance the sensitivity of S gastric cancer cell by directly targeting PI3K/Akt pathway.
authors.affiliation: Department of Radiation Oncology,Chinese PLA General Hospital,Beijing 100853,China2Department of Oncology,Beidaihe Sanatorium of Beijing Military Command,Qinhuangdao,Hebei 066100,China3Department of Gastroenterology,4Department of Radiation Oncology,General Hospital of Beijing Military Command,Beijing 100700,China.
authors.forename: Dian-dian
authors.initials: DD
authors.lastname: Chen
authors.affiliation: Department of Radiation Oncology,Chinese PLA General Hospital,Beijing 100853,China2Department of Oncology,Beidaihe Sanatorium of Beijing Military Command,Qinhuangdao,Hebei 066100,China3Department of Gastroenterology,4Department of Radiation Oncology,General Hospital of Beijing Military Command,Beijing 100700,China.
authors.forename: Lin-chun
authors.initials: LC
authors.lastname: Feng
authors.affiliation: 1. Department of Radiation Oncology,Chinese PLA General Hospital,Beijing 100853,China2Department of Oncology,Beidaihe Sanatorium of Beijing Military Command,Qinhuangdao,Hebei 066100,China3Department of Gastroenterology,4Department of Radiation Oncology,General Hospital of Beijing Military Command,Beijing 100700,China;
authors.forename: Rui
authors.initials: R
authors.lastname: Ye
authors.forename: Yu-qi
authors.initials: YQ
authors.lastname: He
authors.forename: Ya-di
authors.initials: YD
authors.lastname: Wang
mesh_terms: D015153:Blotting, Western; D045744:Cell Line, Tumor; D002470:Cell Survival; D002945:Cisplatin; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm; D006801:Humans; D035683:MicroRNAs; D019869:Phosphatidylinositol 3-Kinases; D015398:Signal Transduction; D013274:Stomach Neoplasms; D015854:Up-Regulation
chemical_list: D002945:Cisplatin; D035683:MicroRNAs; D019869:Phosphatidylinositol 3-Kinases; C532045:MIRN29a microRNA, human